Contraception: Common Problems Faced in Office Practice. Jane S. Sillman, MD Brigham and Women s Hospital

Similar documents
What s New in Adolescent Contraception?

Medical Eligibility for Contraception Use

Contraception for Adolescents: What s New?

LARC: Disclosures. Long Acting Reversible Contraception. Objectives 10/23/2013. I have no relevant financial disclosures

Unintended Pregnancy is Common LEARNING OBJECTIVES. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy And Contraceptive Use

Contraception Choices: An Evidence Based Approach Case Study Approach. Susan Hellier PhD, DNP, FNP-BC, CNE

LEARNING OBJECTIVES. Beyond the Pill: Long Acting Contraception. Distribution Of Contraception Use By Women In The Us. Unintended Pregnancy is Common

Expanding Access to Birth Control: Will Women Get the Care They Need?

Linda Gregg NP, Janet Isabell NP, Sue Montei NP Clinical Reviewers Reproductive Health Unit

Contraception for Obese Women RENEE E. MESTAD, MD, MSCI ACOG DISTRICT II UPSTATE MEETING APRIL 29, 2016

Disclosures. Learning Objectives 4/18/2017 ADOLESCENT CONTRACEPTION UPDATE APRIL 28, Nexplanon trainer for Merck

Contraception. Yolanda Evans MD MPH Assistant Professor of Pediatrics Division of Adolescent Medicine

An Overview of Long Acting Reversible Contraception Methods

The Doctor Is In. Brent N Davidson MD Vice Chair Women s Health Henry Ford Health System Medical Director Family Planning MDCH

Learning objectives. Some fun facts. Presenter Disclosure Information. Become familiar with the newest contraceptive options available

1. Ng M et a l. Global, regional, and national prevalence of overweight and obesity in children and adults during : A systematic analysis

Instruction for the patient

Learning objectives. Some fun facts. Presenter Disclosure Information. Discuss the newest contraceptive options available

U.S. Medical Eligibility Criteria for Contraceptive Use, 2010

CONTRACEPTION OLD FRIENDS, NEW TRENDS

2/4/2011. What is your specialty? A. Family practice B. Internal medicine and subs C. OB/GYN D. Peds E. Surgery and subs

100% Highly effective No cost No side effects

CLINICAL PEARLS IN CONTRACEPTION

Disclosures CONTRACEPTION COUNSELING IN MEDICALLY COMPLEX ADOLESCENTS. Aletha Akers, MD, MPH and Lyndsey Benson, MD, MS

Contraception. Objectives. Unintended Pregnancy. Unintended Pregnancy in the US. What s the Impact? 10/7/2014

Long Acting Reversible Contraception: First Line Care for Adolescents. David A. Levine, MD, FAAP Melissa Kottke, MD, MPH, FACOG

Clinical Challenges in Contraception. Disclosures. Objectives Pharmacists 4/3/2018

Contraception and gynecological pathologies

BEST PRACTICES IN CONTRACEPTIVE COUNSELING

Contraceptive Updates and Recommendations

Contraceptive Updates and Recommendations

Time Topic Speaker Abbreviation

World Health Organization Medical Eligibility for Contraceptive Use. Connie Kraus, PharmD, BCACP Professor (CHS) Director Office of Global Health

Contraception Update: what s new in 2016? Felicity Young MA BSc (Hons) RMN RGN RM NDFSRH A08 Consultant Nurse for Sexual and Reproductive Healthcare

Disclosures. Objectives. Case: Anna. Case: Carla. Case: Beth. Contraception (for the Family Physician) 5/22/2015. Valary Gass, MD.

Adolescent Hot Topics: Contraception

WHAT ARE CONTRACEPTIVES?

CURRENT HORMONAL CONTRACEPTION - LIMITATIONS

BMI and Contraception: What s the Evidence?

Contraceptive case studies. Dr Christine Roke National Medical Advisor Family Planning June 2015

LONG-ACTING REVERSIBLE CONTRACEPTION. Summary Tables

Management of Emergency Contraception (EC)

The number of women using long-acting reversible

BLEEDING PATTERNS AND CONTRACEPTIVE DISCONTINUATION FG MHLANGA MTN ANNUAL MEETING 20 MARCH 2018

Simplifying Vide Contraception. University of Utah Department of Ob/Gyn Post Grad Course February 13, 2017 David Turok

Emergency Contraception THE FACTS

Day of Learning: Current Best Practices for Contraceptive Provision

Family Planning and Infertility

2

A Pharmacist s Update on the Efficacy, Safety and Role of Long-acting Reversible Contraception

Complex Medical Problems? Complex Contraception. Objectives 4/17/2015. Sari Kives, MD,FRCSC ; Alene Toulany, MD, FRCPC

Contraception in Medically Complicated Women

prevalence was 13.8% among females

Fertility control: what do women want?

Learning Objectives. Peri menopause. Menopause Overview. Recommendation grading categories

Disclosures. Contraceptive Method Use, U.S. Best Practices in Contraception: Advances, Tips, and Tricks

BIRTH CONTROL METHOD COMPARISON CHART

Wendy Shen, MD, PhD Refresher Course for the Family Physician April 5, 2018 Coralville, Iowa

Information for Informed Consent for Insertion of a Mirena IUD

Abnormal Uterine Bleeding Case Studies

Birth Control- an Overview. Keith Merritt, MD. Remember, all methods of birth control are safer and have fewer side effects than pregnancy

Topics. Periods Menopause & HRT Contraception Vulva problems

Cue Cards for Counseling Adolescents on Contraception

Orals,Transdermals, and Other Estrogens in the Perimenopause

Picking the Perfect Pill How to Effectively Choose an Oral Contraceptive

Oral Contraceptives. Mike Williams GPST2

Family Planning UNMET NEED. The Nurse Mildred Radio Talk Shows

the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD the IUD your guide to

One-day Essentials Contraception. Dr Paula Briggs, General Practitioner, Clinical Lead Community Sexual Health, Sefton and West Lancashire

The following lesson on contraception (birth control) is not intended to infer that you will be sexually active as a teen. This is information that

The best bike team. period

Contraceptives. Kim Dawson October 2010

Learning Objectives. Expert Medical Advisory Committee. Acknowledgment. A Vignette-Based Approach to Addressing Hormonal Contraception.

Welcome to Mirena. The Mirena Handbook: A Personal Guide to Your New Mirena. mirena.com. Mirena is the #1 prescribed IUD * in the U.S.

Notes to Teacher continued Contraceptive Considerations

FDA-Approved Patient Labeling Patient Information Mirena (mur-ā-nah) (levonorgestrel-releasing intrauterine system)

The Balanced Counseling Strategy Plus: A Toolkit for Family Planning Service Providers Working in High STI/HIV Prevalence Settings.

Maximizing LARC Availability: Bringing the Lessons of the CHOICE Project to Your Community

Global Contraception

Reproductive Health Care: Agenda. Reproductive Health Care: Reproductive Life Plans. Reproductive Life Plans: Provider Prospective

Birth Control in Patients with Congenital Heart Disease

HRT in Perimenopausal Women. Dr. Rubina Yasmin Asst. Prof. Medicine Dhaka Dental College

Table I. Examples of Hormone and Tapering Regimens

Postpartum LARC. (Long Acting Reversible Contraception) NURSING EDUCATION

Removing Unnecessary Barriers to Contraceptive Services

Trudy Bush Lecture: Using Progestins in Clinical Practice. Progestins in Clinical Practice: Outline. NAMS Definitions. FDA Approved Oral Progestins

Contraception Effective Methods of Birth Control

Women s Health: Managing Menopause. Jane S. Sillman, MD Assistant Professor of Medicine Harvard Medical School

Contraception in the medically complicated patient

Birth Control Options Chart

Thrombosis and Women s Health Risk factors, contraceptive pill, HRT and your doctor

Instructions how to use the ESC teach the teachers course and self-learning tool

CODING GUIDELINES FOR CONTRACEPTIVES. Effective June 1, 2017 Version 1.40

International Journal of Research in Pharmaceutical and Nano Sciences Journal homepage:

Instructions how to use the ESC teach the teachers course and self-learning tool

UKMEC SUMMARY TABLE HORMONAL AND INTRAUTERINE CONTRACEPTION

Contraception for Women With Chronic Medical Conditions

Breast Cancer Risk in Patients Using Hormonal Contraception

Use of hormonal therapy in acne

Ardhanu Kusumanto Oktober Contraception methods for gyne cancer survivors

Transcription:

Contraception: Common Problems Faced in Office Practice Jane S. Sillman, MD Brigham and Women s Hospital

Disclosures I have no conflicts of interest

Contraception: Common Problems How to discuss contraception What is the best method for your patient? How to start a contraceptive method Managing side effects Emergency contraception

Key questions When (if ever) do you want to have a child? 1-2 years: Short-acting contraceptive method is most costeffective 3 years or more Long-acting reversible contraception (LARC): IUD or progestin insert (Nexplanon) Depot medroxyprogesterone acetate (DMPA)

Key questions - continued What contraceptive were you thinking of using? Giving a patient what she asked for is associated with higher rates of continuation If she requests any method other than LARC, suggest that she consider LARC if appropriate Managing Contraception 2017-2018

Key questions - continued What would you do if you had an accidental pregnancy? If she would never consider abortion, stress using the most effective contraceptive method (LARC) What methods did you use in the past? What problems did you have with them?

Key questions - continued What are you doing to protect yourself from STIs/HIV? Counsel about adding condoms Do you know about emergency contraception (EC)? Give her a prescription for EC, encourage her to fill it, have it on hand Emphasize relative effectiveness of different methods Do you have any medical problems? Check if any medical contraindication to her method of choice

Your patient s medical eligibility Use the 2016 CDC Medical eligibility criteria MMWR Recomm Rep. 2016;65(4):1. Epub 2016 Jul 29

CDC: Medical contraindications to estrogen Breast cancer DVT DM with vasc. disease or >20 years Endometrial cancer Migraine with aura Uncontrolled HTN Ischemic heart disease Known thrombogenic mutation: Factor V Leiden Smoking in patient > age 35 SLE Complicated valvular heart disease MMWR Recomm Rep. 2016;65(4):1. Epub 2016 Jul 29

What methods are most effective?

Contraceptive Method Highly effective Sterilization 0.5 Implant 0.05 % Women with Unintended Pregnancy in 1 st Yr Typical use IUD 0.2-0.8 Moderately effective DMPA 6.0 Pills: COCs, POPs 9.0 Ring 9.0 Patch 9.0 Managing Contraception 2017-2018

Contraceptive Method % Women with Unintended Pregnancy in 1 st Yr Less effective Diaphragm 12 Male condom 18 Withdrawal 22 Natural family planning: calendar, temp., mucus Typical use 24 Spermicides 28 No method 85 Managing Contraception 2017-2018

How to start contraception NEW: Use the Quick Start for all methods and everyone Start on the day the patient sees you Recommended for pills, patch, ring, injections, implants, IUDs Need to be reasonably certain that patient is not pregnant Managing Contraception 2017-2018

How to be reasonably certain that a woman is not pregnant 1. No intercourse since last menses 2. Using reliable method consistently 3. < 7 days after start of menses 4. Within 4 weeks postpartum 5. < 7 days post abortion or miscarriage 6. Breastfeeding, no menses and < 3 months postpartum 7. Negative urine pregnancy test

Recommended protocol 1. Do urine pregnancy test 2. Offer emergency contraception if unprotected intercourse in preceding 5 days 3. Start method of choice 4. Use back-up contraception (condom or abstinence) for 7 days 5. Repeat urine pregnancy test in 2 weeks Contraception 2017;95:364

LARC: New data on duration of action

Copper IUD (ParaGard): Duration of action Initially approved by FDA for 10 years Now: Women between 25-34: 12 years Women > 35 years old: leave IUD in place till menopause Contraception 2014;89:495

52 mg levonorgestrel IUD (Mirena): New data on duration FDA approval for 5 years Increasing evidence: effective for 7 yrs Concern: younger LNG-IUD users have higher risk of pregnancy Current recommendation Patient aged < 35: 6 years of use Patient aged > 35: 7 years of use Am J Obstet Gynecol June 2017; 216 (6): 586.e1

Etonogestrel implant (Nexplanon): New evidence on duration FDA approval for 3 years Evidence: WHO trial: 204 women with etonogestrel implant use for 5 years: 100% efficacy Effective for 5 years in women of any age Hum Reprod 2016;31(11):2491 Am J Obstet Gynecol 2017 June;216:586.e1

Managing common side effects

Irregular bleeding: Copper IUD Typically causes heavier periods Up to 50% increase in average monthly blood loss. May decrease over time 1 st year removal rate for pain, bleeding: 12% Spotting, frequent or heavy bleeding Rule out pregnancy, infection, cervical lesion, expulsion of IUD Management: NSAIDs for 5-7 days Obstet Gynecol Clin North Am 2015;42(4):593. Epub 2015 Sept 16

Irregular bleeding: levonorgestrel (LNG) IUDs Menstrual changes Menorrhagia improves! Number of spotting, bleeding days 1 st three months: higher than normal After 3-6 months: lower than normal Amenorrhea occurs in 20% of women after one year Removal for bleeding problems in first year: 7.6% Management NSAIDs x 5-7 days Obstet Gynecol Clin North Am 2015;42(4):593. Epub 2015 Sept 16

Irregular bleeding: etonogestrel implant Unpredictable/irregular bleeding frequent, may persist Usually light, well tolerated Management NSAIDs 5-7 days Several cycles of low-dose combined oral contraceptive (COC) if medically eligible MMWR Recomm Rep. 2016;65(4):1. Epub 2016 Jul 29

Irregular bleeding: Injectable (DMPA) users Menstrual Every woman s periods change on DMPA: less menstrual blood loss, 50% have amenorrhea after one year Abnormal bleeding Rule out pregnancy, infection, vaginal or cervical lesion Spotting or light bleeding: NSAIDS for 5-7 days Heavy or prolonged bleeding NSAIDs for 5-7 days Hormonal treatment (if medically eligible): estrogen 1-4 times a day for 5 days, COC pill x 1-2 cycles MMWR Recomm Rep. 2016;65(4):1. Epub 2016 Jul 29

Irregular bleeding: Combined hormonal contraceptive (CHC) Pill, patch, ring Breakthrough bleeding common in 1 st three months: reassure, check re using CHC consistently After three months Evaluate re pregnancy, infection, cervical lesion Cyclic use: 7 days of estrogen Continuous use: 3-4 day hormone-free interval Speroff L,, Darney PD. A Clinical Guide For Contraception, 54 th ed, 2011 MMWR Recomm Rep. 2016;65(4):1. Epub 2016 Jul 29

If irregular bleeding persists or patient finds it unacceptable Reassess re diagnosis Counsel on alternative methods Offer another method if desired

The problem of DVTs Risk is associated with the dose of estrogen: risk of DVT in 50 mcg pills is greater than in 20-35 mcg pills The type of progestin may slightly influence DVT risk The progestins desogestrel (DG) and drospirenone appear to be associated with greater DVT risk than levonorgestrel (LNG)

No COC 10 COC pill w LNG 50 COC pill w DG or drospirenone Hormonal contraception: absolute risks of DVT Absolute risk of DVT/100,000 women per yr 100 Patch 97 Ring 78 Pregnancy 200 BMJ 2011;343:d6423. BMJ 2012;344:e2990

DVT minimizing risk Check that patient is medically eligible for combined hormonal contraception No h/o DVT/PE, no recent major surgery with prolonged immobilization No h/o thrombophilic disorder: Factor V Leiden Combined oral contraceptive pill Avoid pills with progestins desogestrel and drospirenone Start with a low-estrogen pill: 20 mcg

DVT- minimizing risk, continued The patch Delivers 60% more estrogen over a 21 day period than a 35 mcg pill and 3 x more than vaginal ring Would avoid Vaginal ring Lowest serum levels of estrogen and progestin compared to pills, patch OK to use

Hypertension

CDC Medical Eligibility Criteria (MEC) and hypertension Hypertension MEC Adequately controlled HTN 3 Systolic BP 140-159 or diastolic 90-99 3 BP 160/100 or higher 4 Evidence of vascular disease/other CV risk factors 4 3: Risks usually outweigh advantages 4: Unacceptable health risk MMWR Recomm Rep. 2016:65(4):1. Epub 2016 Jul 29

Hypertension and COCs OK to start COC in patient with controlled hypertension with careful monitoring of BP 1% of COC users will develop hypertension Standard evaluation: Check BP after 3 months on COC If BP > 130/80, d/c COC Increased BP due to the COC will return to normal within 1-3 months of discontinuing COCs

Headaches

New onset or worsening headaches in COC user: scenario #1 Focal neurologic symptoms with headache: suggestive of migraine with aura STOP COCs Offer progestin-only or non-hormonal contraception

New onset or worsening headache in COC user: scenario #2 Symptoms only with menses Due to decline in estrogen concentration at time of placebo pills Switch to continuous COC If headaches resolve, continue this treatment Headache 2008;48(8):1186

Headaches are associated with many hormonal contraceptive methods Levonorgestrel IUD: < 16% 1 Etonogestrel implant: 25% 1 DMPA: 9-17% 1,2 Severe headaches can occur Consider switch to another method Vaginal ring: 6% 3 1. Lexicomp Online 2. Headache 2006;46(3):365 3. Obs Gynecol 2002;100:585

Decreased libido

DMPA Hypoestrogenism can cause decreased libido, dyspareunia, hot flashes Management: consider switching to different method Obstet Gynecol 2016 Mar;127(3):563-72

Conflicting data Combined oral contraceptive pills and libido Decreased libido and anorgasmia can occur COCs are associated with decrease in free testosterone but no proof that this causes the decrease in libido Treatment with androgens does not help Management: consider switching to different method Obstet Gynecol 2016 Mar;127(3):563-72 Clin Endocrinol (Oxf). 1980;12(4):327

Weight gain

DMPA can be associated with significant weight gain Weight gain >5% at 6 months associated with increased risk of future weight gain Management Weigh patient at every visit Discuss if gain of 5% or more Eat less, exercise more Consider weight management program If ongoing weight gain, consider switch to another method Contraception 2013 May;87(5):611-24. Epub 2012 Nov 21

No evidence that COCs cause weight gain Average weight gain no different in COC users than in placebo users Gallo MF et al. Cochrane Database Syst Rev 2014

Depression

Levonorgestrel IUDs are associated with mood changes Progestin effect is primarily local but there is some systemic absorption Depression: 4-6% Anxiety: 8% Lexicomp Online

Depression and anxiety can occur with DMPA Depression: 1-<5% More likely in patients with history of premenstrual syndrome or mood disorder Anxiety: 1- <5% Management Ask about mood at follow-up If patient depressed, evaluate suicide potential D/C DMPA if concerned about ongoing use Lexicomp Online. Am J Obstet Gynecol 2000;183(6):1419

Conflicting data on impact of COCs on mood U.S. recent report: beneficial effect of COCs on mood Prospective study of over one million women in Denmark Small increase in antidepressant use in pill users versus nonusers Recommendation: Ask about changes in mood during follow-up visits Am J Epidemiol 2013 Nov;178(9):1378-88. Epub 2013 Sept 15 JAMA Psychiatry 2016;73(11):1154

Problems with adherence

COCs: one missed pill Take the pill ASAP Take remaining pills at usual time, even if need to take 2 pills a day If pill was missed in last week of cycle (e.g. days 15-21 in 28-day pack), finish active pills and start new pack next day No additional contraception is needed Emergency contraception usually not needed CDC MMWR July 29, 2016, Vol. 65:No. 4

COCs: two or more consecutive pills are missed Take most recent missed pill ASAP Take remaining pills at usual time, even if means taking 2 pills on same day Use back-up contraception (condoms) or avoid intercourse until pills have been taken for 7 consecutive days Consider emergency contraception if pills were missed in 1 st week and unprotected sexual intercourse occurred during that week CDC MMWR July 29, 2016, Vol. 65:No. 4

DMPA: returning late for repeat injection DMPA users should return every 13 weeks for repeat injections If woman more than 2 weeks late for injection (>15 weeks): Do pregnancy test Inject DMPA Use back-up contraception (or abstinence) for 7 days MMWR Recomm Rep. 2016;65(4):1. Epub 2016 Jul 29

Emergency Contraception

Ulipristal ( Ella ): Better than Plan B Progestin receptor modulator: suppresses or delays ovulation One 30 mg pill: take no later than 5 days after intercourse More effective than levonorgestrel (Plan B) Very safe Often needs to be ordered by pharmacist Ann Pharmacother 2011;45:780. Contraception 2014 May;89:431

Levonorgestrel: Plan B One-Step One pill: levonorgestrel 1.5 mg Mechanism: inhibits ovulation Take ASAP but can be used up to 5 days after intercourse Availability Brand name: OTC without age restrictions Generic: OTC to people > age 17 and to people of any age in 9 states including MA, VT, NH and 34 countries Cheng L et al. Cochrane Database Syst Rev. 2012

Meta-analysis: ulipristal better than levonorgestrel 3242 women: ulipristal or levonorgestrel within 72 hours of intercourse Pregnancies # % Ulipristal 22 1.4% Levonorgestrel 35 2.2% OR 0.58, CI 0.33-0.99, P=0.046 Lancet 2010;375:555

Advance provision Recommend that patients have home supply of emergency contraceptives in addition to regular contraceptive method Available when/if needed Give prescription at annual exam, encourage patient to fill it J Adolesc Health 2016:58(2):245

BMI affects efficacy of ulipristal (UPA) and levonorgestrel (LNG) BMI Pregnancy, % UPA LNG Normal 1.1 1.3 Overweight 1.1 2.5 Obese 2.6 5.8 Overweight: ulipristal or IUD Obese: IUD best, then ulipristal Contraception 2011;84:363

Copper IUD Most effective EC method Insert up to 5 days after intercourse Mechanism: inflammation Toxic to sperm and egg Interferes with implantation

Emergency contraception: Efficacy If 1000 women have intercourse Method # pregnant % reduction No rx 80 - Levonorg 10 88 Ulipristal 5 94 IUD 1 99

Your patient may ask about these new contraceptive options The one-year vaginal ring: Annovera New mobile app to detect fertile time: Natural Cycles

One-year vaginal ring: Annovera Approved by the FDA 8/10/2018 Combined hormonal contraceptive: segesterone acetate and ethinyl estradiol Post-marketing studies on risk for DVT pending Reusable ring Placed in vagina for 3 weeks followed by 1 week out Washed and stored in a compact case for the 7 days not in use Possible advantage: 1 prescription for whole year www.fda.gov/newsevents/newsroom/pressannouncements/ucm616541.htm

New mobile app to detect fertile time: Natural Cycles Approved by FDA 8/10/2018 Algorithm calculates days of month when likely to be fertile Patient takes daily AM temperature with basal body thermometer, enters temperature and menstrual cycle information into app She needs to abstain or use protection when use protection appears on the app Clinical studies of effectiveness: typical use: 6.5% of women with unintended pregnancy in 1 year www.fda.gov/newsevents/newsroom/pressannouncements/ucm616511.htm

Key Points LARC is best method if pregnancy not wanted in next 2 years Use Quick Start for all contraceptive methods LARC methods last LONGER than we used to think Irregular bleeding can often be treated with NSAIDs COCs and headaches New onset headache with focal neurologic symptoms during active COC pills: STOP COCs Headache during menses: due to estrogen decrease: give continuous COC Emergency contraception: discuss and give prescription

Next steps Ask patient when she wants to have a child. If in > 2 years, recommend LARC for contraception Use the Quick Start Remember current thinking about LARC durations of efficacy Copper IUD: woman > 35 years old at time of placement can leave IUD in place until menopause 52 mg LNG IUD (Mirena) Patient aged < 35: 6 years of use Patient aged > 35: 7 years of use Etonogestrel implant: 5 years

Next steps - continued Irregular bleeding IUD, implant, DMPA: treat with NSAIDS for 5-7 days Cyclic COC: give estrogen Continuous COC: d/c for 3-4 days Headaches on COCs Associated with focal neurologic symptoms: STOP COCs Occurring during time of low estrogen (during menses) Are DUE to drop in estrogen level Treat WITH continuous COC Emergency contraception: tell patient to fill prescription now